CRNX
NASDAQ
US
Crinetics Pharmaceuticals, Inc. - Common Stock
$37.23
▲ +$0.66
(+1.80%)
Vol 1.2M
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$4.4B
ROE
-35.1%
Margin
-22312.8%
D/E
0.00
Beta
0.19
52W
$24–$55
Wall Street Consensus
22 analysts · Apr 20267
Strong Buy
13
Buy
2
Hold
0
Sell
0
Strong Sell
90.9%
Buy Rating
Price Chart
Similar Stocks
BLTE
Belite Bio Inc
$5.6B
TERN
Terns Pharmaceuticals Inc
$4.3B
CORT
Corcept Therapeutics Inc
P/E 34.5
$3.7B
LGND
Ligand Pharmaceuticals Inc
P/E 76.6
$3.7B
AMRX
Amneal Pharmaceuticals Inc
P/E 671.4
$4.0B
INDV
Indivior Pharmaceuticals, Inc
P/E 35.8
$4.5B
GPCR
Structure Therapeutics Inc
$4.2B
EWTX
Edgewise Therapeutics Inc
$2.6B
LQDA
Liquidia Corp
$3.0B
TARS
Tarsus Pharmaceuticals Inc
$3.5B
Earnings
Beat rate: 25.0%
Next Report
May 06, 2026
EPS Estimate: $-1.25
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-1.25 | — | — |
| Dec 2025 | $-1.39 | $-1.29 | +$0.10 |
| Sep 2025 | $-1.28 | $-1.38 | $-0.10 |
| Jun 2025 | $-1.12 | $-1.23 | $-0.11 |
Quarterly Revenue & Earnings
| Quarter | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Revenue | — | $361K | $1.0M | $143K | $6.2M |
| Net Income | -$80.6M | -$96.8M | -$115.6M | -$130.1M | -$122.8M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -32.3% | -32.3% | -32.3% | -32.3% | -35.1% | -35.1% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -11216.0% | -15259.4% | -15259.4% | -15259.4% | -22312.8% | -22312.8% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 17.80 | 17.80 | 17.80 | 17.80 | 15.12 | 15.12 |
Key Ratios
ROA (TTM)
-32.0%
P/S (TTM)
2877.66
P/B
3.6
EPS (TTM)
$-4.53
CF/Share
$-3.61
Rev Growth 3Y
-1.3%
52W High
$54.78
52W Low
$24.10
$24.10
52-Week Range
$54.78
Financial Health
Free Cash Flow
-$93.4M
Net Debt
-$53.0M
Cash
$101.5M
Total Debt
$48.5M
As of Dec 31, 2025
How does CRNX compare to Pharmaceuticals peers?
Peer group: Mid-cap Pharmaceuticals ($2B+) · 25 companies
CRNX valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(30.7)
vs Peers
vs Industry
Fair value
P/S ratio
2877.7
▲
42722%
above
peers
(6.7)
vs Peers
vs Industry
Overvalued
P/B ratio
3.6
▼
31%
below
peers
(5.2)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(3.1%)
vs Peers
vs Industry
Low yield
CRNX profitability vs Pharmaceuticals peers
ROE
-35.1%
▼
35%
below
peers
(-26.1%)
vs Peers
vs Industry
Weak
Net margin
-22312.8%
▼
1538716%
below
peers
(-1.5%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(88.9%)
vs Peers
vs Industry
Top tier
ROA
-32.0%
▼
239%
below
peers
(-9.5%)
vs Peers
vs Industry
Weak
CRNX financial health vs Pharmaceuticals peers
D/E ratio
0.0
▼
100%
below
peers
(27.4)
vs Peers
vs Industry
Low debt
Current ratio
15.1
▲
335%
above
peers
(3.5)
vs Peers
vs Industry
Strong liquidity
Beta
0.2
▼
68%
below
peers
(0.6)
vs Peers
vs Industry
More volatile
CRNX fundamentals radar
CRNX
Peer median
Industry
CRNX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CRNX vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
BETZ STEPHEN F
Officer · Mar 16
10612 shs
STRUTHERS RICHARD SCOTT
Chief Executive Officer · Mar 16
21981 shs
KNIGHT JEFF E
Chief Operating Officer · Mar 16
9911 shs
VIVALDI COELHO ROGERIO
Director · Mar 12
5000 shs
SCHILKE TOBIN
Chief Financial Officer · Mar 03
6713 shs
OKEY STEPHANIE S
Director · Mar 03
3000 shs
SCHILKE TOBIN
Chief Financial Officer · Feb 23
32000 shs
STRUTHERS RICHARD SCOTT
Chief Executive Officer · Feb 23
62000 shs
KNIGHT JEFF E
Chief Operating Officer · Feb 23
34000 shs
BETZ STEPHEN F
Officer · Feb 23
30000 shs
Last 90 days
Top Holders
Top 5: 44.3%FMR, LLC
13.65%
$481.3M
Vanguard Group Inc
8.72%
$307.6M
Wellington Management Group…
7.68%
$270.6M
Blackrock Inc.
7.63%
$269.0M
Farallon Capital Management…
6.62%
$233.4M
As of Dec 31, 2025
Latest News
No related news yet